SG11201809799WA - Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions - Google Patents
Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditionsInfo
- Publication number
- SG11201809799WA SG11201809799WA SG11201809799WA SG11201809799WA SG11201809799WA SG 11201809799W A SG11201809799W A SG 11201809799WA SG 11201809799W A SG11201809799W A SG 11201809799WA SG 11201809799W A SG11201809799W A SG 11201809799WA SG 11201809799W A SG11201809799W A SG 11201809799WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- subunit
- compounds
- voltage
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382199 | 2016-05-06 | ||
PCT/EP2017/060780 WO2017191304A1 (en) | 2016-05-06 | 2017-05-05 | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809799WA true SG11201809799WA (en) | 2018-12-28 |
Family
ID=56024209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809799WA SG11201809799WA (en) | 2016-05-06 | 2017-05-05 | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions |
Country Status (32)
Country | Link |
---|---|
US (1) | US10590140B2 (sl) |
EP (1) | EP3452475B1 (sl) |
JP (1) | JP6926197B2 (sl) |
KR (1) | KR20190024876A (sl) |
CN (1) | CN109526220B (sl) |
AR (1) | AR108387A1 (sl) |
AU (1) | AU2017260305B2 (sl) |
BR (1) | BR112018072755A2 (sl) |
CA (1) | CA3023379A1 (sl) |
CO (1) | CO2018012002A2 (sl) |
CY (1) | CY1123231T1 (sl) |
DK (1) | DK3452475T3 (sl) |
ES (1) | ES2789676T3 (sl) |
HR (1) | HRP20200668T1 (sl) |
HU (1) | HUE051829T2 (sl) |
IL (1) | IL262825A (sl) |
LT (1) | LT3452475T (sl) |
ME (1) | ME03726B (sl) |
MX (1) | MX2018013471A (sl) |
MY (1) | MY196791A (sl) |
PH (1) | PH12018502337A1 (sl) |
PL (1) | PL3452475T3 (sl) |
PT (1) | PT3452475T (sl) |
RS (1) | RS60528B1 (sl) |
RU (1) | RU2018141084A (sl) |
SG (1) | SG11201809799WA (sl) |
SI (1) | SI3452475T1 (sl) |
TN (1) | TN2018000372A1 (sl) |
TW (1) | TWI736619B (sl) |
UA (1) | UA123789C2 (sl) |
WO (1) | WO2017191304A1 (sl) |
ZA (1) | ZA201807653B (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019076904A1 (en) * | 2017-10-16 | 2019-04-25 | Esteve Pharmaceuticals, S.A. | PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN |
SG11202003599UA (en) * | 2017-10-27 | 2020-05-28 | Esteve Pharmaceuticals Sa | New alcoxyamino derivatives for treating pain and pain related conditions |
WO2019110137A1 (en) * | 2017-12-04 | 2019-06-13 | Esteve Pharmaceuticals, S.A. | O-phenoxy and o-benzyloxypropylamino derivatives having activity against pain |
WO2019115008A1 (en) * | 2017-12-12 | 2019-06-20 | Esteve Pharmaceuticals, S.A. | Dialkylaminoarylpiperidinyl-o-phenoxy and o-benzyloxypropylamino derivatives having multimodal activity against pain |
WO2019149919A1 (en) * | 2018-02-05 | 2019-08-08 | Esteve Pharmaceuticals, S.A. | Aminopropoxypiperidinylamido derivatives having multimodal activity against pain |
WO2020089263A1 (en) * | 2018-10-31 | 2020-05-07 | Esteve Pharmaceuticals, S.A. | Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions |
TW202031264A (zh) * | 2018-11-02 | 2020-09-01 | 西班牙商埃斯特維製藥公司 | 用於治療疼痛和疼痛相關疾病的新穎烷氧基氨基吡啶衍生物 |
WO2020089478A1 (en) * | 2018-11-02 | 2020-05-07 | Esteve Pharmaceuticals, S.A. | New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions |
US20220204481A1 (en) * | 2019-02-28 | 2022-06-30 | Osaka University | Protein and/or peptide modification molecule |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9224101A (en) * | 2000-09-27 | 2002-04-08 | Ajinomoto Kk | Benzodiazepine derivative |
CA2488566A1 (en) | 2002-06-27 | 2004-01-08 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder |
EP1724264A1 (en) * | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
ZA200806871B (en) * | 2006-02-14 | 2009-10-28 | Vertex Pharma | Dihydrodiazepines useful as inhibitors of protein kinases |
TW200914457A (en) | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
UY32622A (es) * | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
-
2017
- 2017-05-05 TW TW106114980A patent/TWI736619B/zh not_active IP Right Cessation
- 2017-05-05 DK DK17721680.1T patent/DK3452475T3/da active
- 2017-05-05 KR KR1020187032195A patent/KR20190024876A/ko not_active Application Discontinuation
- 2017-05-05 CA CA3023379A patent/CA3023379A1/en not_active Abandoned
- 2017-05-05 JP JP2019510471A patent/JP6926197B2/ja active Active
- 2017-05-05 SI SI201730239T patent/SI3452475T1/sl unknown
- 2017-05-05 RS RS20200595A patent/RS60528B1/sr unknown
- 2017-05-05 LT LTEP17721680.1T patent/LT3452475T/lt unknown
- 2017-05-05 PT PT177216801T patent/PT3452475T/pt unknown
- 2017-05-05 EP EP17721680.1A patent/EP3452475B1/en active Active
- 2017-05-05 HU HUE17721680A patent/HUE051829T2/hu unknown
- 2017-05-05 MX MX2018013471A patent/MX2018013471A/es unknown
- 2017-05-05 MY MYPI2018704135A patent/MY196791A/en unknown
- 2017-05-05 AU AU2017260305A patent/AU2017260305B2/en not_active Ceased
- 2017-05-05 ME MEP-2020-101A patent/ME03726B/me unknown
- 2017-05-05 TN TNP/2018/000372A patent/TN2018000372A1/en unknown
- 2017-05-05 WO PCT/EP2017/060780 patent/WO2017191304A1/en unknown
- 2017-05-05 CN CN201780042378.XA patent/CN109526220B/zh active Active
- 2017-05-05 SG SG11201809799WA patent/SG11201809799WA/en unknown
- 2017-05-05 US US16/098,244 patent/US10590140B2/en active Active
- 2017-05-05 BR BR112018072755-5A patent/BR112018072755A2/pt not_active IP Right Cessation
- 2017-05-05 PL PL17721680T patent/PL3452475T3/pl unknown
- 2017-05-05 RU RU2018141084A patent/RU2018141084A/ru unknown
- 2017-05-05 UA UAA201811326A patent/UA123789C2/uk unknown
- 2017-05-05 AR ARP170101172A patent/AR108387A1/es unknown
- 2017-05-05 ES ES17721680T patent/ES2789676T3/es active Active
-
2018
- 2018-11-06 PH PH12018502337A patent/PH12018502337A1/en unknown
- 2018-11-06 IL IL262825A patent/IL262825A/en unknown
- 2018-11-14 ZA ZA2018/07653A patent/ZA201807653B/en unknown
- 2018-11-29 CO CONC2018/0012002A patent/CO2018012002A2/es unknown
-
2020
- 2020-04-26 HR HRP20200668TT patent/HRP20200668T1/hr unknown
- 2020-05-25 CY CY20201100472T patent/CY1123231T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201807708SA (en) | Estrogen receptor modulators | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201900043TA (en) | Antibody formulations | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201407110QA (en) | Novel dosage form and formulation of abediterol | |
SG11201407114YA (en) | Novel dosage and formulation |